Allogene Therapeutics (ALLO) Accumulated Expenses (2018 - 2026)
Allogene Therapeutics (ALLO) posted Accumulated Expenses of $23.4 million for Q1 2026, down 17.16% sequentially from $28.2 million in Q4 2025, and down 6.28% YoY from $25.0 million in Q1 2025.
Allogene Therapeutics (ALLO) Accumulated Expenses (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $23.4 million in Q1 2026.
- Quarterly Accumulated Expenses fell 6.28% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.4 million (down 6.28% YoY) and the FY2025 annual result came in at $28.2 million, down 6.26% from the prior year.
- Accumulated Expenses eased to $23.4 million in Q1 2026 per ALLO's latest filing, from $28.2 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $44.6 million in Q1 2023 and troughed at $23.4 million in Q1 2026.
- A 5-year average of $31.1 million and a median of $28.2 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 60.73% in 2023, then sank 44.94% in 2024.
- Over 5 years, Accumulated Expenses stood at $39.7 million in 2022, then retreated by 21.54% to $31.2 million in 2023, then dropped by 3.38% to $30.1 million in 2024, then dropped by 6.26% to $28.2 million in 2025, then dropped by 17.16% to $23.4 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $23.4 million, $28.2 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.76 Mn |
| Mar 31, 2026 | 23.40 Mn |
| Dec 31, 2025 | 28.24 Mn |
| Sep 30, 2025 | 28.13 Mn |
| Jun 30, 2025 | 26.82 Mn |
| Mar 31, 2025 | 24.96 Mn |
| Dec 31, 2024 | 30.13 Mn |
| Sep 30, 2024 | 27.07 Mn |
| Jun 30, 2024 | 24.37 Mn |
| Mar 31, 2024 | 25.03 Mn |
| Dec 31, 2023 | 31.18 Mn |
| Sep 30, 2023 | 31.20 Mn |
| Jun 30, 2023 | 44.26 Mn |
| Mar 31, 2023 | 44.62 Mn |
| Dec 31, 2022 | 39.74 Mn |
| Sep 30, 2022 | 36.94 Mn |
| Jun 30, 2022 | 34.36 Mn |
| Mar 31, 2022 | 27.76 Mn |
| Dec 31, 2021 | 37.50 Mn |
| Sep 30, 2021 | 41.63 Mn |